Published in Biochemistry on March 16, 1999
CYP2C9 genotype-dependent effects on in vitro drug-drug interactions: switching of benzbromarone effect from inhibition to activation in the CYP2C9.3 variant. Mol Pharmacol (2005) 1.08
CYP2C9 protein interactions with cytochrome b(5): effects on the coupling of catalysis. Drug Metab Dispos (2007) 0.93
Phe120 contributes to the regiospecificity of cytochrome P450 2D6: mutation leads to the formation of a novel dextromethorphan metabolite. Biochem J (2004) 0.88
Role of biotransformation in drug-induced toxicity: influence of intra- and inter-species differences in drug metabolism. Drug Metab Pharmacokinet (2010) 0.88
Metabolism of capsaicinoids by P450 enzymes: a review of recent findings on reaction mechanisms, bio-activation, and detoxification processes. Drug Metab Rev (2006) 0.86
Intramolecular heme ligation of the cytochrome P450 2C9 R108H mutant demonstrates pronounced conformational flexibility of the B-C loop region: implications for substrate binding. Biochemistry (2010) 0.84
Functional analysis of phenylalanine residues in the active site of cytochrome P450 2C9. Biochemistry (2008) 0.84
CYP2C9 amino acid residues influencing phenytoin turnover and metabolite regio- and stereochemistry. J Pharmacol Exp Ther (2009) 0.83
Warfarin: history, tautomerism and activity. J Comput Aided Mol Des (2010) 0.80
Line-walking method for predicting the inhibition of P450 drug metabolism. J Med Chem (2006) 0.80
Re-engineering of CYP2C9 to probe acid-base substrate selectivity. Drug Metab Dispos (2008) 0.78
Distal effect of amino acid substitutions in CYP2C9 polymorphic variants causes differences in interatomic interactions against (S)-warfarin. PLoS One (2013) 0.78
Effective virtual screening protocol for CYP2C9 ligands using a screening site constructed from flurbiprofen and S-warfarin pockets. J Comput Aided Mol Des (2007) 0.75
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther (2008) 4.54
Association of CYP2C9*2 with bosentan-induced liver injury. Clin Pharmacol Ther (2013) 3.29
Group II introns designed to insert into therapeutically relevant DNA target sites in human cells. Science (2000) 2.86
Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics (1994) 2.55
Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol (1992) 2.41
Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos (1999) 2.18
Isolation of bedsoniae from the joints of patients with Reiter's syndrome. Proc Soc Exp Biol Med (1966) 2.17
Retracted New findings of the correlation between acupoints and corresponding brain cortices using functional MRI. Proc Natl Acad Sci U S A (1998) 2.05
Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry (1998) 1.93
Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone. J Clin Invest (1974) 1.85
Isoform specificity of trimethylamine N-oxygenation by human flavin-containing monooxygenase (FMO) and P450 enzymes: selective catalysis by FMO3. Biochem Pharmacol (1998) 1.80
Improved non-parametric statistical methods for the estimation of Michaelis-Menten kinetic parameters by the direct linear plot. Biochem J (1977) 1.75
Purification and characterization of a unique isozyme of cytochrome P-450 from liver microsomes of ethanol-treated rabbits. J Biol Chem (1982) 1.71
Enzymatic degradation of heme. Oxygenative cleavage requiring cytochrome P-450. Biochemistry (1972) 1.71
Attenuation of CCl(4)-induced hepatic fibrosis by GdCl(3) treatment or dietary glycine. Am J Physiol Gastrointest Liver Physiol (2001) 1.64
Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol (2001) 1.59
Hydroxylation of p-nitrophenol by rabbit ethanol-inducible cytochrome P-450 isozyme 3a. Mol Pharmacol (1986) 1.58
The domain structure and retrotransposition mechanism of R2 elements are conserved throughout arthropods. Mol Biol Evol (1999) 1.58
Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys (1996) 1.56
On the stoichiometry of the oxidase and monooxygenase reactions catalyzed by liver microsomal cytochrome P-450. Products of oxygen reduction. J Biol Chem (1984) 1.52
The teaching of medical ethics. J Med Ethics (1976) 1.51
Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics (1997) 1.47
Effects of the wine polyphenolics quercetin and resveratrol on pro-inflammatory cytokine expression in RAW 264.7 macrophages. Biochem Pharmacol (1999) 1.44
Systemic fat embolism after renal homotransplantation and treatment with corticosteroids. N Engl J Med (1965) 1.42
Gamma-glutamyl carboxylase (GGCX) tagSNPs have limited utility for predicting warfarin maintenance dose. J Thromb Haemost (2007) 1.41
A biologic comparison of polyglactin 910 and polyglycolic acid synthetic absorbable sutures. Surg Gynecol Obstet (1975) 1.38
Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther (1994) 1.36
Laparoscopic cystectomy: initial report on a new treatment for the retained bladder. J Urol (1992) 1.35
The mechanism of the interaction between amiodarone and warfarin in humans. Clin Pharmacol Ther (1992) 1.30
Nalidixic acid inhibition of DNA transfer in Escherichia coli K12. Cold Spring Harb Symp Quant Biol (1968) 1.29
CYP2E1 is not involved in early alcohol-induced liver injury. Am J Physiol (1999) 1.29
Evaluation of distribution-free confidence limits for enzyme kinetic parameters. J Theor Biol (1978) 1.27
Warfarin metabolites: the anticoagulant activity and pharmacology of warfarin alcohols. J Lab Clin Med (1973) 1.27
Fat embolism and osteonecrosis. Orthop Clin North Am (1985) 1.25
Flavone antagonists bind competitively with 2,3,7, 8-tetrachlorodibenzo-p-dioxin (TCDD) to the aryl hydrocarbon receptor but inhibit nuclear uptake and transformation. Mol Pharmacol (1999) 1.24
Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects. Clin Pharmacol Ther (1992) 1.23
Role of cytochrome P-450 2E1 in ethanol-, carbon tetrachloride- and iron-dependent microsomal lipid peroxidation. Hepatology (1992) 1.22
Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J Pharmacol Exp Ther (1994) 1.22
Stereochemical course of the biosynthesis of 1-aminocyclopropane-1-carboxylic acid. I. Role of the asymmetric sulfonium pole and the alpha-amino acid center. Biochem Biophys Res Commun (1984) 1.20
Cytochrome P-450--catalyzed formation of delta 4-VPA, a toxic metabolite of valproic acid. Science (1987) 1.18
Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies. Drug Metab Dispos (1996) 1.18
Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies. Drug Metab Dispos (1996) 1.17
Alternative splicing determines the function of CYP4F3 by switching substrate specificity. J Biol Chem (2001) 1.15
Absolute configurations of the four warfarin alcohols. J Med Chem (1972) 1.15
Treatment of trichomoniasis with a single dose of nimorazole (nitrimidazine). Br J Vener Dis (1972) 1.14
The warfarin-sulfinpyrazone interaction: stereochemical considerations. Clin Pharmacol Ther (1986) 1.14
Immunoquantitation of FMO1 in human liver, kidney, and intestine. Drug Metab Dispos (2000) 1.13
Warfarin metabolism in man: identification of metabolites in urine. J Clin Invest (1970) 1.11
Osseous avascular necrosis associated with systemic abnormalities. Arthritis Rheum (1966) 1.11
Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome p450 active sites. Drug Metab Dispos (2001) 1.11
Identification of novel substrates for human cytochrome P450 2J2. Drug Metab Dispos (2009) 1.10
Laparoscopic diverticulectomy: preliminary report of a new approach for the treatment of bladder diverticulum. J Urol (1992) 1.10
Assessment of barriers to bone marrow donation by unrelated African-American potential donors. Biol Blood Marrow Transplant (2001) 1.08
Immunochemical evidence for induction of the alcohol-oxidizing cytochrome P-450 of rabbit liver microsomes by diverse agents: ethanol, imidazole, trichloroethylene, acetone, pyrazole, and isoniazid. Proc Natl Acad Sci U S A (1985) 1.08
Regio- and stereoselective epoxidation of arachidonic acid by human cytochromes P450 2C8 and 2C9. J Pharmacol Exp Ther (1994) 1.08
Effects of Ginkgo biloba extract (EGb 761) and quercetin on lipopolysaccharide-induced signaling pathways involved in the release of tumor necrosis factor-alpha. Biochem Pharmacol (2001) 1.08
Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19. Drug Metab Dispos (1996) 1.06
Changes in dyspnea-fatigue ratings as indicators of quality of life in the treatment of congestive heart failure. Am J Cardiol (1989) 1.06
Identification of ethanol-inducible P-450 isozyme 3a as the acetone and acetol monooxygenase of rabbit microsomes. J Biol Chem (1985) 1.05
Oxidation of acetaminophen to its toxic quinone imine and nontoxic catechol metabolites by baculovirus-expressed and purified human cytochromes P450 2E1 and 2A6. Chem Res Toxicol (1998) 1.05
Catalytic activity of cytochrome P-450 isozyme 3a isolated from liver microsomes of ethanol-treated rabbits. Oxidation of alcohols. J Biol Chem (1982) 1.03
Prenatal nicotine effects on memory in rats: pharmacological and behavioral challenges. Brain Res Dev Brain Res (1996) 1.03
Degradation of cytochrome P450 2E1: selective loss after labilization of the enzyme. Arch Biochem Biophys (1992) 1.03
Formation of 19(S)-, 19(R)-, and 18(R)-hydroxyeicosatetraenoic acids by alcohol-inducible cytochrome P450 2E1. J Biol Chem (1993) 1.02
Differential expression of ob mRNA in rat adipose tissues in response to insulin. Biochem Biophys Res Commun (1996) 1.01
Stereoselective interaction of phenylbutazone with [12C/13C]warfarin pseudoracemates in man. J Clin Invest (1980) 1.01
Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis. Clin Pharmacol Ther (2012) 1.00
Comparison of six rabbit liver cytochrome P-450 isozymes in formation of a reactive metabolite of acetaminophen. Biochem Biophys Res Commun (1983) 0.98
The metabolic fate of warfarin: studies on the metabolites in plasma. Ann N Y Acad Sci (1971) 0.98
Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem Res Toxicol (1994) 0.98
In vitro methods for assessing human hepatic drug metabolism: their use in drug development. Drug Metab Rev (1993) 0.97
Intramolecular isotope effects for benzylic hydroxylation of isomeric xylenes and 4,4'-dimethylbiphenyl by cytochrome P450: relationship between distance of methyl groups and masking of the intrinsic isotope effect. Biochemistry (1997) 0.97
Involvement of human cytochrome P450 2D6 in the bioactivation of acetaminophen. Drug Metab Dispos (2000) 0.97
Focused ultrasound modifications of neural circuit activity in a mammalian brain. Ultrasound Med Biol (1998) 0.97
Effects of thyroid hormone on GLUT4 glucose transporter gene expression and NIDDM in rats. Endocrinology (1997) 0.97
Inhibition of human liver microsomal epoxide hydrolase by valproate and valpromide: in vitro/in vivo correlation. Clin Pharmacol Ther (1989) 0.97
Endotoxemia in rats is associated with induction of the P4504A subfamily and suppression of several other forms of cytochrome P450. Drug Metab Dispos (1996) 0.96
Metabolism of nitrosamines by purified rabbit liver cytochrome P-450 isozymes. Cancer Res (1985) 0.96
Vitamin K-dependent carboxylation of peptide-bound glutamate. The active species of "CO2" utilized by the membrane-bound preprothrombin carboxylase. J Biol Chem (1977) 0.96
Metabolic fate of phenprocoumon in humans. J Pharm Sci (1985) 0.96
Theory for the observed isotope effects from enzymatic systems that form multiple products via branched reaction pathways: cytochrome P-450. Biochemistry (1989) 0.96
The mechanism of the warfarin-rifampin drug interaction in humans. Clin Pharmacol Ther (1987) 0.96
Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease. Pharmacogenet Genomics (2008) 0.95
Cytochrome P450-dependent desaturation of lauric acid: isoform selectivity and mechanism of formation of 11-dodecenoic acid. Chem Biol Interact (1998) 0.95
Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen. Drug Metab Dispos (1997) 0.95
Attenuation estimation in reflection: progress and prospects. Ultrason Imaging (1984) 0.95
Mechanism-based inactivation of cytochrome P450 2B1 by 8-methoxypsoralen and several other furanocoumarins. Biochemistry (1998) 0.94
Modification by focused ultrasound pulses of electrically evoked responses from an in vitro hippocampal preparation. Brain Res (1991) 0.94